Description
Indication & Scope
Myfortic® Mycophenolate Sodium Enteric-coated Tablets provides immunosuppressive prophylaxis for acute rejection after renal transplantation, applied to reduce the risk of renal allograft rejection in adult transplant patients.
- Mechanism: Selectively inhibits lymphocyte purine synthesis pathway, suppresses T and B lymphocyte activation and proliferation, and exerts potent specific immune suppression effect on transplant rejection.
- Drug class: High-selectivity immunosuppressant, renal transplantation anti-rejection agent
- Clinical use: First-line standardized immunosuppressive maintenance therapy for adult renal allograft transplantation in combination with calcineurin inhibitors and hormones.
| Generic Name | Mycophenolate Sodium Enteric-coated Tablets |
| Brand Name | Myfortic® |
| Ingredient | Mycophenolate Sodium |
| Dosage Form | Tablets |
| Package | Myfortic:
180mg*50 tablets/box; 180mg*120 tablets/box; 360mg*50 tablets/box; 360mg*120 tablets/box 0.18g (calculated by C₁₇H₂₀O₆) *120 tablets/box |
| Conditions Treated | Postoperative acute rejection prevention of renal transplantation |
| Taboos | Contraindicated in mycophenolate ingredient hypersensitivity; strictly prohibited in pregnancy and breastfeeding; contraindicated in severe hematological abnormalities |
| Place of origin | China/Oeflinger Strasse 44, 79664 Wehr, Germany |
| Prescription type | Prescription-only |
| Storage Conditions | Store at 20°C–25°C, tightly sealed, protected from light and humid environment |
| Manufacturer | Sichuan Kelun Pharmaceutical Co., Ltd./Novartis Pharma Produktions GmbH |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20244004; HJ20160051; HJ20160075 |
| Approval Date | Jun 11, 2024; May 5, 2023 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: Standard adult maintenance dose: 720 mg twice daily.
Time: Fixed twice-daily administration, 1 hour before or 2 hours after meals.
Instructions for use: Swallow whole tablets without breaking; avoid combined use with magnesium-aluminum antacids; monitor blood routine regularly.
Interaction:Cholestyramine reduces drug bioavailability; combined immunosuppressants increase opportunistic infection risk.
Side effects:
1. Typical adverse reactions include diarrhea, abdominal pain, leukopenia and increased infection susceptibility.
2. Rare reactions include anemia and gastrointestinal ulcer.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What core effect does Mycophenolate Sodium Enteric-coated Tablets exert after kidney transplantation?
Myfortic effectively suppresses abnormal immune responses and reduces the incidence of acute renal transplant rejection.
What is the optimal administration time relative to meals when using Mycophenolate Sodium Enteric-coated Tablets?
Administration is recommended 1 hour before meals or 2 hours after meals for maximum drug absorption.
What routine examination is required during long-term anti-rejection medication of Mycophenolate Sodium Enteric-coated Tablets?
Regular blood routine examination is required to monitor white blood cell count changes.
What drug combination will reduce the efficacy of Mycophenolate Sodium Enteric-coated Tablets?
Concomitant use of cholestyramine reduces the oral bioavailability and therapeutic effect of the drug.
Myfortic® | Mycophenolate Sodium Enteric-coated Tablets | Prevention of Immune Rejection in Kidney Transplantation | DengYueRX
INN: Mycophenolate Sodium Enteric-coated Tablets
Indications: Prevention of immune rejection in kidney transplantation
Dosage Form: Tablets
Strength: 180mg/tablet; 0.18g (calculated by C₁₇H₂₀O₆) /tablet
Price range: $132.17 through $167.46
